Duggan D E, Yeh K C, Matalia N, Ditzler C A, McMahon F G
Clin Pharmacol Ther. 1975 Aug;18(2):205-9. doi: 10.1002/cpt1975182205.
Bioavailabilities of dexamethasone tablets and elixir in man were evaluated by each of 3 model-independent methods of pharmacokinetic analysis employing plasma and urinary values as determined by radioimmune assay. There were no significant differences among the results determined by the 3 methods nor between the respective availabilities of the two formulations; the latter averaged 82.6 +/- 17.7% for the elixir formulation and 78.0 +/- 12.1% for tablets.
采用放射免疫分析法测定血浆和尿液值,通过三种独立的药代动力学分析模型方法,对人地塞米松片剂和酏剂的生物利用度进行了评估。三种方法测定的结果之间以及两种制剂各自的生物利用度之间均无显著差异;后者酏剂制剂的平均生物利用度为82.6±17.7%,片剂为78.0±12.1%。